Capricor Therapeutics, Inc. (CAPR) — SEC Filings
Capricor Therapeutics, Inc. (CAPR) — 36 SEC filings. Latest: 8-K (Dec 5, 2025). Includes 21 8-K, 6 10-Q, 3 SC 13G.
View Capricor Therapeutics, Inc. on SEC EDGAR
Overview
Capricor Therapeutics, Inc. (CAPR) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 3, 2025: On December 3, 2025, Capricor Therapeutics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and a Regulation FD disclosure. No specific financial figures or new material events were detailed in the provided excerpt.
Sentiment Summary
Across 36 filings, the sentiment breakdown is: 2 bullish, 2 bearish, 32 neutral. The dominant filing sentiment for Capricor Therapeutics, Inc. is neutral.
Filing Type Overview
Capricor Therapeutics, Inc. (CAPR) has filed 21 8-K, 6 10-Q, 2 10-K, 3 SC 13G, 3 SC 13G/A, 1 DEF 14A with the SEC between Jan 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (36)
Risk Profile
Risk Assessment: Of CAPR's 27 recent filings, 2 were flagged as high-risk, 13 as medium-risk, and 12 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $0 |
| Net Income | -$74.9M |
| EPS | N/A |
| Debt-to-Equity | 0.51 |
| Cash Position | $19.5M |
| Operating Margin | N/A |
| Total Assets | $126.4M |
| Total Debt | $42.6M |
Key Executives
- Michael Kelliher
- Dr. Linda T. Griffith
- Dr. Linda D. Smith
Industry Context
Capricor Therapeutics operates in the highly competitive and capital-intensive biotechnology sector, focusing on developing novel cell and exosome-based therapies. The industry is characterized by long development cycles, significant R&D investment, and stringent regulatory oversight. Success hinges on clinical trial outcomes, regulatory approvals, and the ability to secure substantial funding to advance pipeline candidates.
Top Tags
financial-reporting (5) · financials (4) · biotech (4) · 8-K (3) · Biotechnology (3) · disclosure (3) · financial-statements (2) · exhibits (2) · Duchenne Muscular Dystrophy (2) · Pharmaceuticals (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss | $74.9M | Increased from $33.4M in 2024 for the nine months ended September 30, 2025 |
| Revenue | $0 | Decreased from $11.1M in 2024 for the nine months ended September 30, 2025 |
| Research and Development Expenses | $61.3M | Increased from $35.4M in 2024 for the nine months ended September 30, 2025 |
| General and Administrative Expenses | $17.7M | Increased from $10.6M in 2024 for the nine months ended September 30, 2025 |
| Accumulated Deficit | $274.7M | Increased from $199.8M at December 31, 2024 |
| Cash, Cash Equivalents, and Marketable Securities | $98.6M | Total liquidity as of September 30, 2025 |
| Cash and Cash Equivalents | $19.5M | Increased from $11.3M at December 31, 2024 |
| Marketable Securities | $79.1M | Decreased from $140.2M at December 31, 2024 |
| Proceeds from Sales/Maturities of Marketable Securities | $197.4M | Key source of cash for nine months ended September 30, 2025 |
| Shares Outstanding | 45,718,475 | As of November 7, 2025 |
| Shares Authorized | 3,634,646 | under the 2025 Equity Incentive Plan adopted May 31, 2025 |
| Period End Date | 2025-06-30 | date of the reported financial results |
| Total Assets | $45.58M | As of March 31, 2025 |
| Total Liabilities | $45.68M | As of March 31, 2025 |
| Gross Proceeds | $100.0M | Raised from the public offering before expenses. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Capricor Therapeutics, Inc. (CAPR)?
Capricor Therapeutics, Inc. has 36 recent SEC filings from Jan 2024 to Dec 2025, including 21 8-K, 6 10-Q, 3 SC 13G. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of CAPR filings?
Across 36 filings, the sentiment breakdown is: 2 bullish, 2 bearish, 32 neutral. The dominant sentiment is neutral.
Where can I find Capricor Therapeutics, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Capricor Therapeutics, Inc. (CAPR) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Capricor Therapeutics, Inc.?
Key financial highlights from Capricor Therapeutics, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for CAPR?
The investment thesis for CAPR includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Capricor Therapeutics, Inc.?
Key executives identified across Capricor Therapeutics, Inc.'s filings include Michael Kelliher, Dr. Linda T. Griffith, Dr. Linda D. Smith.
What are the main risk factors for Capricor Therapeutics, Inc. stock?
Of CAPR's 27 assessed filings, 2 were flagged high-risk, 13 medium-risk, and 12 low-risk.
What are recent predictions and forward guidance from Capricor Therapeutics, Inc.?
Forward guidance and predictions for Capricor Therapeutics, Inc. are extracted from SEC filings as they are enriched.